株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

PharmaPoint:片頭痛 - EU5ヶ国における医薬品の予測と市場分析

PharmaPoint: Migraine - 5EU Drug Forecast and Market Analysis to 2023

発行 GlobalData 商品コード 299712
出版日 ページ情報 英文 149 Pages
即納可能
価格
本日の銀行送金レート: 1USD=115.27円で換算しております。

2016年12月31日まで 年末キャンペーン割引: GlobalData社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
PharmaPoint:片頭痛 - EU5ヶ国における医薬品の予測と市場分析 PharmaPoint: Migraine - 5EU Drug Forecast and Market Analysis to 2023
出版日: 2014年03月31日 ページ情報: 英文 149 Pages
概要

片頭痛の治療薬市場は、ジェネリック医薬品で飽和状態で、上市されている残りのブランド薬は、慢性片頭痛の治療薬Botoxを除き、今後数年間で独占性を失うと見られています。片頭痛の治療薬市場は、2023年までに37億米ドル規模まで拡大し、CAGRで3.6%の成長が予測されています。

当レポートでは、EU5ヶ国における片頭痛の治療薬市場について調査分析し、疾病の概要とガイドライン、競合情勢、主要薬剤の詳細情報(製品説明、安全性、有効性)、SWOT分析、売上高予測、影響分析(動向、促進要因・抑制要因)などを提供して、概略以下の構成でお届けいたします。

第1章 目次

第2章 イントロダクション

第3章 疾病の概要

  • 病因・病態生理
    • 病因
    • 病態生理
    • 予後
  • 症状
    • 前兆
    • 前駆症状
    • 頭痛
    • 後発症状

第4章 疾病の管理

  • 治療の概要
    • 急性片頭痛
    • 予防的片頭痛
  • フランス
    • 診断
    • 臨床診療
  • ドイツ
    • 診断
    • 臨床診療
  • イタリア
    • 診断
    • 臨床診療
  • スペイン
    • 診断
    • 臨床診療
  • 英国
    • 診断
    • 臨床診療

第5章 競合評価

  • 概要
  • 戦略的競合企業の評価
  • 製品プロファイル - 主要ブランド
    • Triptans
    • Imitrex (sumatriptan)
    • Zomig (zolmitriptan)
    • Amerge (naratriptan)
    • Maxalt (rizatriptan)
    • Axert (almotriptan)
    • Frova (frovatriptan)
    • Relpax (eletriptan)
    • Ergot Alkaloids
    • Beta Blockers
    • Anti-Epileptics
    • Antidepressants
    • Calcium Channel Antagonists
    • Botox (onabotulinum toxin A)

第6章 機会とアンメットニーズ

  • 概要
  • アンメットニーズのギャップ分析

第7章 パイプライン評価

  • 概要
  • 臨床開発中の有望な薬剤
    • RHB-103
    • Lasmiditan
    • MK-1602
    • RT-001
    • NXN-188

第8章 市場の見通し

  • フランス
  • ドイツ
  • イタリア
  • スペイン
  • 英国

第9章 付録

図表

目次
Product Code: GDHC228CFR

The migraine market is saturated with generic drugs, and the remaining branded products already on the market are expected to lose exclusivity during the next few years, with the exception of Botox for chronic migraine, which is expected to maintain its leading position in terms of sales. However, reformulations of mature products as well as new classes of therapies are anticipated to launch during the forecast period and these will contribute to the market growth. By 2023, the migraine market will grow to $3.7 billion at a compound annual growth rate (CAGR) of 3.6%, with the US continuing to dominate the market as a result of higher drug prices and a large migraine population. Some of the new treatments are expected to target the key unmet needs but opportunities will remain for further treatment choices especially drugs that will offer an improved safety and side-effects profile.

Each of the countries included in this report provide guidelines for the treatment of migraine. According to GlobalData's high-prescriber survey, the US, UK and Japan strongly adhere to their own national guidelines; however, the majority of the physicians from other EU countries (France, Germany, Italy and Spain) follow European guidelines such as the European Headache Federation (EHF) and European Federation of Neurological Societies (EFNS) guidelines.

Scope

  • Overview of Migraine including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on the key drugs in 5EU including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for the top drugs in 5EU (the UK, France, Italy, Spain, Germany) from 2012-2023.
  • Analysis of the impact of key events as well the drivers and restraints affecting the US Migraine market.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return.
  • Stay ahead of the competition by understanding the changing competitive landscape for Migraine.
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential.
  • Make more informed business decisions from insightful and in-depth analysis of drug performance.
  • Obtain sales forecast for drugs from 2012-2023 in 5EU (the UK, France, Italy, Spain, Germany).

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
    • 3.1.3. Prognosis
  • 3.2. Symptoms
    • 3.2.1. Premonitory Phase
    • 3.2.2. Aura Phase
    • 3.2.3. Headache Phase
    • 3.2.4. Postdrome Phase

4. Disease Management

  • 4.1. Treatment Overview
    • 4.1.1. Acute Migraine Treatment
    • 4.1.2. Preventive Migraine Treatment
  • 4.2. France
    • 4.2.1. Diagnosis
    • 4.2.2. Clinical Practice
  • 4.3. Germany
    • 4.3.1. Diagnosis
    • 4.3.2. Clinical Practice
  • 4.4. Italy
    • 4.4.1. Diagnosis
    • 4.4.2. Clinical Practice
  • 4.5. Spain
    • 4.5.1. Diagnosis
    • 4.5.2. Clinical Practice
  • 4.6. UK
    • 4.6.1. Diagnosis
    • 4.6.2. Clinical Practice

5. Competitive Assessment

  • 5.1. Overview
  • 5.2. Strategic Competitor Assessment
  • 5.3. Product Profiles- Major Brands
    • 5.3.1. Triptans
    • 5.3.2. Imitrex (sumatriptan)
    • 5.3.3. Zomig (zolmitriptan)
    • 5.3.4. Amerge (naratriptan)
    • 5.3.5. Maxalt (rizatriptan)
    • 5.3.6. Axert (almotriptan)
    • 5.3.7. Frova (frovatriptan)
    • 5.3.8. Relpax (eletriptan)
    • 5.3.9. Ergot Alkaloids
    • 5.3.10. Beta Blockers
    • 5.3.11. Anti-Epileptics
    • 5.3.12. Antidepressants
    • 5.3.13. Calcium Channel Antagonists
    • 5.3.14. Botox (onabotulinum toxin A)

6. Opportunity and Unmet Need

  • 6.1. Overview
    • 6.1.1. A Lack of Acute Therapies for Patients with or at Risk of Cardiovascular Disorders
    • 6.1.2. Lack of Acute Therapies for Patients Unresponsive to Triptan Medication
    • 6.1.3. Lack of Diagnostic Tools Causes Misdiagnosis
    • 6.1.4. Physician Education
    • 6.1.5. Effective and Well-Tolerated Prophylactic Therapies
  • 6.2. Unmet Needs Gap Analysis
    • 6.2.1. Acute Therapies for Patients with or at Risk of Cardiovascular Disorders and for Patients Unresponsive to Triptan Medication
    • 6.2.2. Effective and Well-Tolerated (Migraine-Specific) Preventive Therapies
    • 6.2.3. Physician Education
    • 6.2.4. Diagnostic Tools

7. Pipeline Assessment

  • 7.1. Overview
  • 7.2. Promising drugs in clinical development
    • 7.2.1. RHB-103
    • 7.2.2. Lasmiditan
    • 7.2.3. MK-1602
    • 7.2.4. RT-001
    • 7.2.5. NXN-188

8. Market Outlook

  • 8.1. France
    • 8.1.1. Forecast
    • 8.1.2. Key Events
    • 8.1.3. Driver and Barriers
  • 8.2. Germany
    • 8.2.1. Forecast
    • 8.2.2. Key Events
    • 8.2.3. Driver and Barriers
  • 8.3. Italy
    • 8.3.1. Forecast
    • 8.3.2. Key Events
    • 8.3.3. Driver and Barriers
  • 8.4. Spain
    • 8.4.1. Forecast
    • 8.4.2. Key Events
    • 8.4.3. Driver and Barriers
  • 8.5. United Kingdom
    • 8.5.1. Forecast
    • 8.5.2. Key Events
    • 8.5.3. Driver and Barriers

9. Appendix

  • 9.1. Bibliography
  • 9.2. Abbreviations
  • 9.3. Methodology
  • 9.4. Forecasting Methodology
    • 9.4.1. Diagnosed Migraine Patients
    • 9.4.2. Percent Drug-treated Patients
    • 9.4.3. Drugs Included in Each Therapeutic Class
    • 9.4.4. Launch and Patent Expiry Dates
    • 9.4.5. General Pricing Assumptions
    • 9.4.6. Individual Drug Assumptions
    • 9.4.7. Generic Erosion
    • 9.4.8. Pricing of Pipeline agents
  • 9.5. Physicians and Specialists Included in this Study
  • 9.6. Survey of Prescribing Physicians
  • 9.7. About the Authors
    • 9.7.1. Author
    • 9.7.2. Reviewer
    • 9.7.3. Global Head of Healthcare
  • 9.8. About GlobalData
  • 9.9. Disclaimer

List of Tables

  • Table 1: Classification of Migraine Subtypes
  • Table 2: Diagnostic Criteria for Migraine with Aura
  • Table 3: Diagnostic Criteria for Migraine without Aura
  • Table 4: Treatment Guidelines for Migraine
  • Table 5: Most Prescribed Drugs for Migraine by Class in the Major Markets, 2013
  • Table 6: Product Profile - Triptans
  • Table 7: Triptans SWOT Analysis, 2013
  • Table 8: Product Profile - Ergot Alkaloids
  • Table 9: Ergot Alkaloids SWOT Analysis, 2013
  • Table 10: Product Profile - Beta Blockers
  • Table 11: Beta Blockers SWOT Analysis, 2013
  • Table 12: Product Profile - Anti-Epileptics
  • Table 13: Anti-Epileptics SWOT Analysis, 2013
  • Table 14: Product Profile - Antidepressants
  • Table 15: Antidepressants SWOT Analysis, 2013
  • Table 16: Product Profile-Calcium Channel Antagonists
  • Table 17: Calcium Channel Antagonists SWOT Analysis, 2013
  • Table 18: Product Profile - Botox
  • Table 19: Botox SWOT Analysis, 2013
  • Table 20: Overall Unmet Needs - Current Level of Attainment
  • Table 21: Clinical Unmet Needs - Gap Analysis, 2013
  • Table 22: Migraine - Promising Late-Stage Pipeline, 2013
  • Table 23: Comparison of Therapeutic Classes in Development for Migraine, 2013
  • Table 24: Product Profile - RHB-103
  • Table 25: RHB-103 SWOT Analysis, 2013
  • Table 26: Product Profile - Lasmiditan
  • Table 27: Lasmiditan SWOT Analysis, 2013
  • Table 28: Product Profile - MK-1602
  • Table 29: MK-1602 SWOT Analysis, 2013
  • Table 30: Product Profile - RT-001
  • Table 31: RT-001 SWOT Analysis, 2013
  • Table 32: Product Profile - NXN-188
  • Table 33: NXN-188 SWOT Analysis, 2013
  • Table 34: Sales Forecasts ($m) for Migraine in France, 2012-2023
  • Table 35: Key Events Impacting Sales for Migraine in France, 2012-2023
  • Table 36: Migraine Market - Drivers and Barriers, 2012-2023
  • Table 37: Sales Forecasts ($m) for Migraine in Germany, 2012-2023
  • Table 38: Key Events Impacting Sales for Migraine in Germany, 2012-2023
  • Table 39: German Migraine Market - Drivers and Barriers, 2012-2023
  • Table 40: Sales Forecasts ($m) for Migraine in Italy, 2012-2023
  • Table 41: Key Events Impacting Sales for Migraine in Italy, 2012-2023
  • Table 42: Italian Migraine Market - Drivers and Barriers, 2012-2023
  • Table 43: Sales Forecasts ($m) for Migraine in Spain, 2012-2023
  • Table 44: Key Events Impacting Sales for Migraine in Spain, 2012-2023
  • Table 45: Spanish Migraine Market - Drivers and Barriers, 2012-2023
  • Table 46: Sales Forecasts ($m) for Migraine in the UK, 2012-2023
  • Table 47: Key Events Impacting Sales for Migraine in the UK, 2012-2023
  • Table 48: UK Migraine Market - Drivers and Barriers, 2012-2023
  • Table 49: Key Launch or Approval Dates
  • Table 50: Key Patent Expiries
  • Table 51: Physicians Surveyed, By Country

List of Figures

  • Figure 1: Migraine Treatment Algorithm in the 7MM
  • Figure 2: Competitive Assessment of Late-Stage Pipeline Agents in Migraine, 2012-2023
  • Figure 3: Sales for Migraine in France by Drug Class, 2012-2023
  • Figure 4: Sales for Migraine in Germany by Drug Class, 2012-2023
  • Figure 5: Sales for Migraine in Italy by Drug Class, 2012-2023
  • Figure 6: Sales for Migraine in Spain by Drug Class, 2012-2023
  • Figure 7: Sales for Migraine in the UK by Drug Class, 2012-2023
Back to Top